About CARBOGEN AMCIS
CARBOGEN AMCIS is a company based in Bubendorf (Switzerland) founded in 1990 was acquired by Dishman Group in August 2006. CARBOGEN AMCIS has raised $4.36 million across 2 funding rounds from investors including HHS, Dishman Group and Solutia. CARBOGEN AMCIS offers products and services including API Manufacturing, Drug Product Development, and Specialities Manufacturing. CARBOGEN AMCIS operates in a competitive market with competitors including Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
- Headquarter Bubendorf, Switzerland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.36 M (USD)
in 2 rounds
-
Latest Funding Round
$4.36 M (USD), Series A
Sep 02, 2021
-
Investors
HHS
& 2 more
-
Employee Count
Employee Count
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CARBOGEN AMCIS
CARBOGEN AMCIS offers a comprehensive portfolio of products and services, including API Manufacturing, Drug Product Development, and Specialities Manufacturing.
Develops and manufactures active pharmaceutical ingredients for clinical use.
Offers formulation and analytical services for sterile drug products.
Produces Vitamin D analogs and cholesterol derivatives under GMP standards.
People of CARBOGEN AMCIS
Unlock access to complete
Software Development Team
41 people
Product Management Team
21 people
Senior Team
20 people
Human Resources and Administration
12 people
Project Team
11 people
Sales and Marketing
11 people
Manager Team
9 people
Head Team
8 people
Unlock access to complete
Funding Insights of CARBOGEN AMCIS
CARBOGEN AMCIS has successfully raised a total of $4.36M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.36 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $4.4M
-
First Round
First Round
(18 Sep 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Series A - CARBOGEN AMCIS | Valuation |
investors |
|
| Sep, 2009 | Amount | Grant - CARBOGEN AMCIS | Valuation |
investors |
Investors in CARBOGEN AMCIS
CARBOGEN AMCIS has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Dishman Group and Solutia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Additives, functional products, specialty chemicals, and fibers are provided.
|
Founded Year | Domain | Location | |
|
CDMO offering its services for the development of APIs and intermediates
|
Founded Year | Domain | Location |
Investments & Acquisitions by CARBOGEN AMCIS
Financial Statements - CARBOGEN AMCIS
Carbogen Amcis Comparisons
Competitors of CARBOGEN AMCIS
CARBOGEN AMCIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| domain | founded_year | HQ Location |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| domain | founded_year | HQ Location |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| domain | founded_year | HQ Location |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| domain | founded_year | HQ Location |
CDMO with a focus on early phase drug product development
|
|
| domain | founded_year | HQ Location |
Biopharma regulatory affairs, quality control, and strategy services are provided.
|
Frequently Asked Questions about CARBOGEN AMCIS
CARBOGEN AMCIS was founded in 1990 and raised its 1st funding round 19 years after it was founded.
CARBOGEN AMCIS is headquartered in Bubendorf, Switzerland. It is registered at Bubendorf, Basel-landschaft, Switzerland.
CARBOGEN AMCIS is a funded company, having raised a total of $4.36M across 2 funding rounds to date. The company's 1st funding round was a Grant of $105.77K, raised on Sep 18, 2009.
Founded in 1990 and based in Bubendorf, Switzerland, CARBOGEN AMCIS operates as a contract development and manufacturing organization in the pharmaceutical sector. Services encompass chemical process research, API production for preclinical, clinical, and commercial stages, and analytical support including chromatography and parenteral formulations. The company was acquired by Dishman Pharma in 2006 and functions as its subsidiary, focusing on high-potency compounds.
CARBOGEN AMCIS's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
CARBOGEN AMCIS offers API Manufacturing, Drug Product Development, and Specialities Manufacturing.
CARBOGEN AMCIS has 3 investors. Key investors include HHS, Dishman Group, and Solutia.